NDC product
Daybue
NDC 63090-660 · Acadia Pharmaceuticals Inc.
Key facts
| Product NDC | 63090-660 |
|---|---|
| Proprietary name | Daybue |
| Nonproprietary name | trofinetide |
| Substances | TROFINETIDE |
| Dosage form | SOLUTION |
| Route | ORAL |
| Labeler | Acadia Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA217026 |
| Pharmacologic classes | Cytochrome P450 3A4 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA] |
| Marketing start | Mar 10, 2023 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: